Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1557939/000155793916000095/a2016q210q.htm
September 2016
September 2016
August 2016
July 2016
June 2016
June 2016
May 2016
April 2016
March 2016
February 2016
![]() | ![]() |
• | Revenue for the second quarter of 2016 of $472.4 million, grew 2.3% as reported on a GAAP basis and 2.8% on a constant currency basis, from the prior-year period |
• | Revenue from Advanced Wound Therapeutics ("AWT") grew 0.2% as reported on a GAAP basis and 0.8% on a constant currency basis, led by solid volume growth in advanced wound devices compared to the prior-year period |
• | Revenue from Regenerative Medicine ("RM") grew 11.0% as reported on a GAAP basis and on a constant currency basis, due primarily to higher volumes associated with breast reconstruction procedures |
• | Net loss was $20.1 million, as reported on a GAAP basis, up from $17.6 million net loss in the prior-year period, due primarily to the loss on extinguishment of debt and professional fees related to our second quarter debt transactions |
• | Adjusted EBITDA1 of $171.1 million, declined 1.0% as reported from the prior-year period and 0.8% on a constant currency basis, primarily due to investments in our franchise structure and sales force to drive growth |
• | Building strong partnerships with leading plastic surgeons to develop and educate on an innovative breast reconstruction technique resulted in the Regenerative Medicine Team achieving the highest growth rate since 2012. Recent sales initiatives and new product introductions also contributed to strong growth in breast reconstruction procedures. |
• | Acelity launched the TIELLE™ Foam Dressing Family in the United States, which includes seven new advanced dressings that can be used on a variety of wounds. This launch is strategically important, allowing the Company to further diversify the business, giving clinicians more efficient and cost effective patient solutions with Acelity’s industry leading AWT portfolio. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1557939/000155793916000095/a2016q210q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Acelity L.P. Inc..
Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits
CIK: 1557939
Form Type: 10-Q Quarterly Report
Accession Number: 0001557939-16-000095
Submitted to the SEC: Tue Aug 02 2016 5:29:56 PM EST
Accepted by the SEC: Tue Aug 02 2016
Period: Thursday, June 30, 2016
Industry: Surgical And Medical Instruments And Apparatus